| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | MS-275 | CTRPv2 | pan-cancer | AAC | 0.0023 | 0.9 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.0024 | 0.9 |
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | S-Trityl-L-cysteine | FIMM | pan-cancer | AAC | -0.01 | 1 |
| mRNA | CHM-1 | CTRPv2 | pan-cancer | AAC | 0.0019 | 1 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.0026 | 1 |
| mRNA | DBeQ | CTRPv2 | pan-cancer | AAC | 0.0021 | 1 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.002 | 1 |